↓ Skip to main content

Dove Medical Press

Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer

Overview of attention for article published in OncoTargets and therapy, June 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (72nd percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

patent
3 patents
wikipedia
1 Wikipedia page

Citations

dimensions_citation
51 Dimensions

Readers on

mendeley
90 Mendeley
Title
Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
Published in
OncoTargets and therapy, June 2017
DOI 10.2147/ott.s114714
Pubmed ID
Authors

LE Dockery, CC Gunderson, KN Moore

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 90 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 90 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 16 18%
Student > Bachelor 15 17%
Other 7 8%
Student > Master 7 8%
Student > Doctoral Student 4 4%
Other 10 11%
Unknown 31 34%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 17 19%
Pharmacology, Toxicology and Pharmaceutical Science 11 12%
Chemistry 8 9%
Medicine and Dentistry 7 8%
Agricultural and Biological Sciences 7 8%
Other 8 9%
Unknown 32 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 October 2023.
All research outputs
#5,449,088
of 25,382,440 outputs
Outputs from OncoTargets and therapy
#278
of 3,016 outputs
Outputs of similar age
#88,402
of 330,503 outputs
Outputs of similar age from OncoTargets and therapy
#7
of 77 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,503 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 77 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.